Search This Blog

Friday, September 27, 2019

Mizuho Securities Starts Arcus Biosciences (RCUS) at Buy

Mizuho Securities analyst Mara Goldstein initiates coverage on Arcus Biosciences (NYSE: RCUS) with a Buy rating and a price target of $22.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.